Interim Results for Gastric Cancer Treatment With Ramucirumab Plus Pembrolizumab

Warren Fingrut, MD, discussed a study looking at HLA antibody burden among patients with blood cancers, particularly women who have carried multiple pregnancies.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.

In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.

Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.

Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.